The triple intervention refers to a strategy of using three antiretroviral drugs together during pregnancy and breastfeeding to prevent mother-to-child transmission of HIV. Before this approach became standard, shorter and simpler drug regimens were used, but they left significant gaps in protection, especially during breastfeeding. The triple intervention changed the calculus for HIV-positive mothers in resource-limited settings by cutting transmission rates roughly in half compared to older two-drug approaches.
How the Triple Intervention Works
Rather than relying on one or two antiretroviral drugs given only around the time of delivery, the triple intervention combines three medications that attack HIV at different points in its life cycle. In the landmark Kesho Bora study, conducted across Burkina Faso, Kenya, and South Africa, the specific combination was zidovudine, lamivudine, and lopinavir boosted with ritonavir. Mothers took these drugs twice daily starting late in pregnancy and continued through breastfeeding, up to six and a half months after delivery.
The logic is straightforward: by suppressing the virus in the mother’s body more effectively, fewer copies of HIV reach the baby during birth or through breast milk. Single-dose or two-drug regimens could reduce viral load temporarily, but they didn’t maintain suppression long enough to cover the extended breastfeeding period that is common and culturally important in many parts of the world.
Key Trial Results
The Kesho Bora study, published in The Lancet Infectious Diseases, enrolled 824 HIV-positive pregnant women between 2005 and 2008. These women had moderate immune suppression, with CD4 cell counts between 200 and 500. Half received the triple antiretroviral regimen, while the other half received the older standard of zidovudine plus a single dose of nevirapine at delivery.
At six weeks after birth, 3.3% of infants in the triple drug group had acquired HIV, compared to 5.0% in the older regimen group. The real difference showed up at 12 months: transmission was 5.4% in the triple group versus 9.5% in the comparison group. That gap widened further when researchers looked at the combined outcome of HIV transmission or infant death, which was 10.2% with triple therapy compared to 16.0% with the older approach.
Among mothers who breastfed, the benefit was especially clear. The 12-month transmission rate was 5.6% with triple therapy versus 10.7% with the standard regimen. This mattered enormously in settings where formula feeding is impractical or unsafe due to lack of clean water, and where not breastfeeding can itself raise infant mortality.
Safety During Breastfeeding
One of the biggest concerns with any drug regimen during breastfeeding is whether it harms the baby. The Kesho Bora trial found that serious adverse events in both mothers and infants were similar between the triple drug group and the comparison group. A separate study in Kisumu, Kenya (the KiBS trial) specifically examined whether triple antiretroviral therapy was tolerable for breastfeeding women over six months. No child deaths or serious adverse events were clearly linked to the medications.
In that Kenyan study, 80% of mothers had undetectable viral loads by six months postpartum, up from just 5% at enrollment. Women were counseled to exclusively breastfeed for the first five and a half months and then wean over two weeks. Most followed this guidance, with 87% of infants having stopped breastfeeding by six months. The researchers noted that stopping breastfeeding was sometimes difficult for cultural reasons, fear of stigma, or lack of resources for alternative feeding.
Tradeoffs for Maternal Health
While the triple intervention clearly protects infants, the picture for maternal health is slightly more nuanced. A large trial published in the New England Journal of Medicine, enrolling nearly 3,500 HIV-positive pregnant women, found that full antiretroviral therapy during pregnancy resulted in significantly lower rates of early HIV transmission to infants compared to a single drug alone. However, mothers on the combination regimens experienced higher rates of certain side effects, including blood abnormalities and abnormal lab values. The rates of serious complications remained low overall, and the side effect profiles between different triple drug combinations were similar to each other.
For most women, the benefit of preventing transmission to their child outweighs these risks. Current guidelines now recommend that all pregnant women living with HIV receive combination antiretroviral therapy regardless of their immune status, and that they continue treatment for life rather than stopping after breastfeeding ends.
From Triple Intervention to Triple Elimination
The success of the triple antiretroviral approach for HIV laid the groundwork for a broader public health strategy. The World Health Organization now promotes what it calls “triple elimination,” which aims to simultaneously end mother-to-child transmission of three infections: HIV, syphilis, and hepatitis B. This initiative bundles testing for all three infections into routine prenatal care visits, followed by prompt treatment for any positive results, counseling for women and their partners, safe delivery practices, follow-up care for exposed infants (including hepatitis B vaccination at birth), and lifelong treatment for mothers who need it.
The shift from treating these infections separately to addressing them together reflects a practical reality: the same prenatal care visit that screens for HIV can just as easily screen for syphilis and hepatitis B, and many of the same health system investments, such as trained midwives, reliable drug supply chains, and infant follow-up programs, serve all three goals at once.